Respiratory
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life
Regional ILD Masterclass Ep.1: Rationale for Early Antifibrotic Treatment in PF-ILD – Dr. Felix Chua
30/04/2024 | Author: Boehringer Ingelheim
Document ID: PC-TH-104743
RELATED CONTENT
4:55